Oncternal Therapeutics Inc (NASDAQ:ONCT)

0.82
Delayed Data
As of Sep 23
 -0.029 / -3.39%
Today’s Change
0.69
Today|||52-Week Range
4.63
-63.88%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$43.6M

Company Description

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.

Contact Information

Oncternal Therapeutics, Inc.
12230 El Camino Real
San Diego California 92130
P:(858) 434-1113
Investor Relations:

Employees

Shareholders

Mutual fund holders9.14%
Individual stakeholders3.69%
Other institutional14.02%

Top Executives

James B. BreitmeyerPresident, Chief Executive Officer & Director
Richard Glenn VincentChief Financial Officer, Secretary & Treasurer
Gunnar F. KaufmannChief Scientific Officer
Rajesh KrishnanChief Technology Officer
Salim YazjiChief Medical Officer